Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 3, 1998, Pages 3-7

  Honigfeld, Gilbert ^a   Arellano, Felix ^b,c   Sethi, Jitender ^b   Bianchini, Anthony ^b   Schein, Jeffrey ^b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BENZATROPINE MESILATE; CHLORPROMAZINE; CLOZAPINE;

AGRANULOCYTOSIS; ARTICLE; CLINICAL PRACTICE; DRUG EFFECT; DRUG INDICATION; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; HUMAN; LEUKOCYTE COUNT; LEUKOPENIA; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; SCHIZOPHRENIA;

ADVERSE DRUG REACTION REPORTING SYSTEMS; AGRANULOCYTOSIS; CLOZAPINE; DATABASES, FACTUAL; DRUG APPROVAL; DRUG INFORMATION SERVICES; HUMANS; LEUKOCYTE COUNT; LEUKOPENIA; REGISTRIES; SCHIZOPHRENIA; UNITED STATES;

EID: 0031969105     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19
2. Rosenstein MJ, Milazzo-Sayre LJ, Manderscheid RW. Care of persons with schizophrenia: a statistical profile. Schizophr Bull 1989;15:45-58
3. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine (Clozaril Collaborative Study). Arch Gen Psychiatry 1988;45:789-796
4. Stephens P. A review of clozapine: an antipsychotic for treatment-resistant schizophrenia. Compr Psychiatry 1990;31(4):315-326
5. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988;8(suppl 4):52S-56S
6. Mills MJ, Eth S. Legal liability with psychotropic drug use: extrapyramidal syndromes and tardive dyskinesia. J Clin Psychiatry 1987;48(suppl 9): 28-33
7. Meltzer HY. Treatment of the neuroleptic-nonresponsive schizophrenic patient. Schizophr Bull 1992;18:515-542
8. Kane JM, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: results of a US multicenter trial. Psychopharmacology 1989;99:S60-S63
9. Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry 1992;160(suppl 17):41-45
10. Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Therapy 1984;1(2):77-97
11. Gerlach J, Koppelhus P, Helweg E, et al. Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 1974;50:410-424
12. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. Am J Psychiatry 1997;154(4, suppl): 1-62
13. Claghorn J, Honigfeld G, Abuzzahab FS Sr, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987;7: 377-384
14. Gerlach J, Thorsen K, Fog R. Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 1975;40:341-350
15. Levin H, Chengappa KNR, Kambhampati RK, et al. Should chronic treatment-refractory akathisia be an indication for the use of clozapine in schizophrenic patients? J Clin Psychiatry 1992;53:248-251
16. Gerbino L, Shopsin B, Collora M. Clozapine in the treatment of tardive dyskinesia: an interim report. In: Fann W, Smith R, David J, et al, eds. Tardive Dyskinesia: Research & Treatment. New York, NY: SP Medical & Scientific Books; 1980:475-489
17. Lieberman J, Kane J, Johns C, et al. Clozapine: clinical evidence of novel effects. Clin Neuropharmacol 1986;9(suppl 4):140-141
18. Griffith RW, Saameli K. Clozapine and agranulocytosis [letter]. Lancet 1975;2:657
19. Amsler HA, Teerenhovi L, Barth E, et al. Agranulocytosis in patients treated with clozapine: a study of the Finnish epidemic. Acta Psychiatr Scand 1977;56:241-248
20. Lieberman JA, Johns CA, Kane JM, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271-277
21. Shopsin B, Feiner N. The current status of clozapine [letter]. Psychopharmacol Bull 1983;19(4):563-564
22. Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology (Berl) 1989;99:S118-S121
23. Krupp P, Barnes P. Clozapine-associated agranulocytosis: risk and aetiology. Br J Psychiatry 1992;160(suppl 17):38-40
24. Honigfeld G. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis. Psychiatr Serv 1996;47(1):52-56
25. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997;8:671-677
26. Dale DC. Abnormalities of leukocytes. In: Isselbacher K, Adams R, Braunwald E, et al, eds. Harrison's Principles of Internal Medicine. Tokyo, Japan: Kosaido Printing; 1980:283-290
27. Lieberman JA, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. Psychiatr Q 1992;63(1):51-70
28. Alvir JMJ, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 1993;329:162-167
29. Safferman A, Lieberman J, Alvir J, et al. Rechallenge in clozapine-induced agranulocytosis. J Clin Psychopharmacol 1992;339:1296-1297
30. Clozaril. Physicians' Desk Reference. Montvale, NJ: Medical Economics Company; 1998:1834-1838
31. Lieberman JA, Yunis J, Egea E, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Arch Gen Psychiatry 1990;47:945-948
32. Claas FHJ, Abbott PA, Witvliet MD, et al. No direct clinical relevance of the human leucocyte antigen (HLA) system in clozapine-induced agranulocytosis. Drug Saf 1992;7(suppl 1):3-6
33. de la Chapelle A, Kari C, Nurminen M, et al. Clozapine-induced agranulocytosis: a genetic and epidemiologic study. Hum Genet 1977;37:183-194
34. Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. Eur J Clin Pharmacol 1977;11:199-201
35. Idänpään-Heikkilä J, Alhava E, Olkinoura M, et al. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977;11:193-198
36. Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 1990;336:785-787
37. Adams PC. Mianserin-induced agranulocytosis [letter]. BMJ 1982;285: 208-209
38. Kuperman S, Black DW, Burns TL. Excess mortality among formerly hospitalized child psychiatric patients. Arch Gen Psychiatry 1988;45:277-282
39. Black DW, Fisher R. Mortality in DSM-IIIR schizophrenia. Schizophr Res 1992;7:109-116
40. Allebeck P. Schizophrenia: a life-shortening disease. Schizophr Bull 1989; 15:81-89
41. Mortensen PB, Juel K. Mortality and causes of death in schizophrenic patients in Denmark. Acta Psychiatr Scand 1990;81:372-377
42. Mortensen P, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry 1993;163:183-189
43. Black D. Mortality in schizophrenia - the Iowa record-linkage study: a comparison with general population mortality. Psychosomatics 1988;29: 55-60
44. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990;16:571-589
45. Newman SC, Bland RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991;36:239-245
46. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995;152:183-190
47. Galdi J, Reider RO, Silber D, et al. Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychol Med 1981;11:713-728
48. Hirsch S. Depression 'revealed' in schizophrenia [Comments]. Br J Psychiatry 1982;140:421-424
49. Kimmel SE, Calabrese JR, Woyshville MJ, et al. Clozapine in treatment-refractory mood disorders. J Clin Psychiatry 1994;55(9, suppl B):91-93
50. Zarate CA Jr, Tohen M, Banov MD, et al. Is clozapine a mood stabilizer? J Clin Psychiatry 1995;56:108-112
51. Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry 1994;55:295-300